We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Metabolic differences between Asian and Caucasian patients on clozapine treatment.
- Authors
Subramaniam, Mythily; Chee Ng; Siow-Ann Chong; Mahendran, Rathi; Lambert, Tim; Pek, Elaine; Chan Yiong Huak
- Abstract
Objective To establish if there are ethnic differences in the various metabolic disturbances that are common with clozapine treatment. Method Forty subjects (20 Asians and 20 Caucasians) with a diagnosis of schizophrenia were recruited for the study. Clozapine blood levels as well as fasting blood glucose, lipid levels, and liver function tests were established. Other clinical parameters such as blood pressure and Body Mass Index (BMI) were recorded for each patient. Results The mean clozapine dose was significantly higher in the Caucasian subjects (432.5 ± 194.7 mg) as compared to the Asian subjects (175.6 ± 106.9 mg) (p < 0.001) while the mean weight-corrected dose for Asian patients was lower (3.0 ± 1.9 and 5.0 ± 2.1 mg/kg, respectively, p = 0.005). There were, however, no ethnic differences in the mean plasma clozapine concentration (415.3 ± 185.8 ng/ml in Caucasians and 417.1 ± 290.8 ng/ml in Asians). BMI were significantly higher in Caucasians, as were the number of subjects with hypertension; levels of hepatic enzymes were higher in the Asian group. Conclusions Not only are there pharmacokinetic differences between Asian and Caucasian patients receiving clozapine, but there may also be differential emergence of certain metabolic abnormalities like hypertension and weight gain in these two ethnic groups. However, the effects of life style including diet and exercise cannot be excluded. Copyright © 2007 John Wiley & Sons, Ltd.
- Subjects
CLOZAPINE; THERAPEUTICS; SCHIZOPHRENIA treatment; GLUCOSE; ENZYMES
- Publication
Human Psychopharmacology: Clinical & Experimental, 2007, Vol 22, Issue 4, p217
- ISSN
0885-6222
- Publication type
Article
- DOI
10.1002/hup.842